[ad_1]
The clinical trial in Brazil for the CoronaVac vaccine, produced by China’s Sinovac against Covid-19, was suspended after health authorities reported a “serious adverse” incident, according to Mediafax.
Brazilian regulator Anvisa said the incident occurred on October 29, but did not provide further details.
Dimas Covas, director of Butantan, Brazil’s main medical research institute, told local media that the suspension of the trial was linked to a death, but insisted the death was not related to the vaccine, Reuters reported.
The news of the suspension came shortly after the US pharmaceutical company Pfizer announced that the vaccine they had developed had shown a 90% effectiveness.
CoronaVac, developed by the Chinese pharmaceutical company Sinovac Biotech, is one of the world’s leading competitors in the development and implementation of an effective Covid-19 vaccine.
Late studies for the Sinovac vaccine are also underway in Indonesia and Turkey, but neither of them have announced a suspension.
China is already using the Sinovac vaccine to immunize thousands of people.
Publisher: AC
